Sequenom, Inc. Updates Second Half 2015 Revenue Outlook

SAN DIEGO, Sept. 25, 2015 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, provides its current revenue outlook for the second half of 2015.

The Company is updating its revenue expectations for the second half of the year to a range between $57 million and $61 million, bringing 2015 annual revenue expectations to a range between $127 million and $131 million.

Drivers for the updated expectations include increased competition and price compression in the noninvasive prenatal testing (NIPT) market.

"2015 has been and is a pivotal year for Sequenom. It is also a year of transition," stated Dirk van den Boom, Interim President and CEO of Sequenom.  "Importantly, we continue to make significant progress implementing our strategy in reproductive health, including advancing our in-network strategy, and improving our reach into the broader NIPT market with new product launches.  Within reproductive health, I am particularly enthusiastic about our MaterniT™ GENOME laboratory-developed test. This launch represents an exciting new test that should allow for future growth in the NIPT market. Moreover, we continue to make progress in oncology.  We plan on elucidating in greater detail both our reproductive health business and our oncology opportunity at the September 28 Analyst Day. In parallel, we are focused on increasing our organizational effectiveness, and operational efficiency to ensure Sequenom's industry leadership position."

The Company expects to announce its financial results for the third quarter on November 4, 2015, and will provide further discussion of its operating results at that time.

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is committed to enabling healthier lives through the development of innovative products and services.  The Company serves patients and physicians by providing early patient management information. To learn how Sequenom is interpreting the genome to improve your life, visit www.sequenom.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the development of innovative products and services,  the anticipated revenue for the second half of 2015, the ability to make significant progress in implementing the Company's strategy, the ability to advance the Company's in-network strategy and improve its reach into the broader NIPT market, the potential for the launch of MaterniT GENOME to provide future growth, the ability to make progress on the Company's oncology development efforts and the ability to increase organizational effectiveness and operational efficiency to ensure Sequenom's leadership position and growth.    Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.  Risks are described more fully in the Company's filings with the Securities and Exchange Commission, including without limitation the Company's most recent Quarterly Report on Form 10-Q and other documents subsequently filed with or furnished to the Securities and Exchange Commission.  All forward-looking statements contained in this press release speak only as of the date on which they were made.  The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Logo - http://photos.prnewswire.com/prnh/20040415/SQNMLOGO 

SOURCE Sequenom, Inc.

Related Links

http://www.sequenom.com